New Delhi: The Serum Institute of India said on Thursday that it had decided to stop testing the Covid-19 Vaccine, as AstraZeneca stopped the process. In collaboration with AstraZeneca and Oxford University, the Serum Institute is developing a vaccine against Covid-19. Three trials of AstraZeneca have been halted on Wednesday after its adverse effects on a person involved in vaccine testing in the UK. AstraZeneca has not described the nature of adverse reactions in the patient.
AstraZeneca also issued a statement saying, “This is a routine hurdle, as nothing is yet understood about the illness of the person involved in the testing.” This led the Central Drug Regulator to Serum Institute of India (SII) to stop the clinical trial of the Oxford Covid-19 vaccine in other countries by the pharma company AstraZeneca and not to report the vaccine’s “serious adverse effects”. Show cause notice was issued.
Drug Controller General of India, Dr. V.G. Somani has asked the Serum Institute in the show cause notice to suspend the permission given for Phase II and Phase III vaccine testing in the country until the safety of patients is guaranteed.
SII gave this answer to the show cause notice
In connection with the show-cause notice issued by DCGI, the Serum Institute of India said in a statement, “We are working as per the instructions of DCGI and as of now we have not been asked to stop the trial. If DCGI has any security concerns We will follow their instructions and follow the standard procedure. “
Regarding AstraZeneca’s withholding of tests in the UK, the Serum Institute said in its statement, “We cannot comment much on the trials taking place in the UK, but they are currently withheld for review and are expected to start early.” Will be. “
The DGCA last month allowed the Serum Institute in Pune to conduct human clinical trials of Phase II and III of the corona virus infection vaccine.
